Glycoprofiling of cancer biomarkers: Label-free electrochemical lectin-based biosensors by Pihíková, Dominika et al.
Open Chem., 2015; 13: 636–655
Review Article Open Access
Dominika Pihíková, Peter Kasák, Jan Tkac*
Glycoprofiling of cancer biomarkers: Label-free 
electrochemical lectin-based biosensors  
Abstract: Glycosylation of biomolecules is one of the 
most prevalent post- and co-translational modification in 
a human body, with more than half of all human proteins 
being glycosylated. Malignant transformation of cells 
influences glycosylation machinery resulting in subtle 
changes of the glycosylation pattern within the cell 
populations as a result of cancer. Thus, an altered terminal 
glycan motif on glycoproteins could provide a warning 
signal about disease development and progression 
and could be applied as a reliable biomarker in cancer 
diagnostics. Among all highly effective glycoprofiling 
tools, label-free electrochemical impedance spectroscopy 
(EIS)-based biosensors have emerged as especially 
suitable tool for point-of-care early-stage cancer 
detection. Herein, we highlight the current challenges 
in glycoprofiling of various cancer biomarkers by 
ultrasensitive impedimetric-based biosensors with low 
sample consumption, low cost fabrication and simple 
miniaturization. Additionally, this review provides a short 
introduction to the field of glycomics and lectinomics and 
gives a brief overview of glycan alterations in different 
types of cancer. 
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1 Introduction
Carbohydrates are an essential part of every living organism 
and are considered to be the most abundant organic 
molecules found in nature [1-3]. It is widely known that 
glycans modulate or mediate cell-cell or cell-biomolecule 
interactions, cell signalling, host-pathogen interactions, 
disease progression or metastasis [4-7]. Changes in the 
glycosylation, mediated by multiple enzymes, play critical 
roles in regulation of numerous biological processes. 
Oligosaccharides may covalently link to a protein 
backbone in order to stabilize, functionalize it and create 
highly specific sites for biorecognition. There are two 
main types of glycan attachments to glycoproteins: (i) 
N-linked glycosylation e.g. glycans are covalently bound 
to asparagine residues in a  consensus sequence Asn-
X-Ser/Thr (X can be any amino acid except for proline) 
via N-acetylglucosamine (N-GlcNAc); and (ii) O-linked 
glycosylation e.g. attachment of glycans to the hydroxyl 
groups of serine or threonine [8]. Glycosylation is quite a 
complex process catalysed by glycosyltransferases in the 
endoplasmic reticulum (ER)-Golgi apparatus [9,10]. 
The structural variety of glycans derives from 
the various ways in which monosaccharides can be 
linked together and from many available isomers of 
monosaccharides [9]. Covalent glycosidic bond can be 
designed in two possible positions at an anomeric carbon; 
i.e. via either an α- or a β- glycosidic linkage. A vast 
complexity of glycans can be illustrated by a theoretical 
number of all possible saccharides formed from 4 
building blocks, when 4 different amino acids can form 
24 different tetrapeptides, but four different hexoses may 
potentially generate 35,560 unique tetrasaccharides [1,11]. 
In addition, glycans can be enzymatically modified, which 
further increases the number of possible saccharidic units 
potentially present in biological systems [12]. 
In order to understand the function of glycans on 
a molecular level, advanced mass spectrometry (MS), 
liquid chromatography (LC), capillary electrophoresis 
(CE), microarray techniques, and biosensors have been 
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employed [13,14]. Glycan arrays and arrays of glycan-
binding biomolecules have become “a must have” 
component for highly robust and parallel glycoprofiling 
in glycomics and for glycoprofiling of various diseases 
[3,15-20]
2 Lectins
Lectins are ubiquitous natural proteins specifically 
recognizing and binding carbohydrate complexes. 
Structural studies indicated that the carbohydrate-
binding activity of lectins was generated by a limited 
polypeptide segment designated as the carbohydrate 
recognition domain (CRD) [1,21]. Most lectins interact 
with terminal non-reducing carbohydrate residues of 
a  glycoprotein and glycolipid component of the cell 
membrane. Variety of lectins are localized in different 
parts of the organism, depending on their functional 
role (e.g. intracellular lectins are involved in protein 
trafficking, membrane-bound lectins mediate host-
pathogen interactions, etc.) [22]. The term lectin is 
evolved from the Latin word legere meaning to choose, 
pick or select [23]. Furthermore, these carbohydrate-
binding molecules are able to agglutinate cells (e.g. 
erythrocytes). It is believed that the earliest description of 
ability to agglutinate erythrocytes was by Peter Hermann 
Stillmark in 1888 [21]. He described the agglutination 
activity of toxin Ricinus communis in his doctoral thesis. 
However, the modern age of lectinomics began almost 
one hundred years later [1].
Lectins have been isolated from various sources, such 
as plants, bacteria, viruses, and animals [18,24]. Plant 
lectins are the biggest family of lectins; one of the best 
characterized types of plant lectin are the ones isolated 
from Legeminosae sp. The Leguminosae lectins are Ca2+- and 
Mn2+-dependent metalloproteins, such as concanavalin 
A (ConA), lentil lectin (LCA), soybean agglutinin (SBA), 
and others [24]. Some of the plant lectins (Ricinus communis 
agglutinin, and lectin from Abrus precatorius) exhibit 
toxic effect to animal cells [25]. Animal lectins belong 
to endogenous lectins and are further classified into 
a C-type (Ca2+-dependent) and S-type (sulphhydryl-
dependent galectins usually occurring in a soluble 
form) [9,25]. Viral lectins are known as hemagglutinins 
and the influenza virus hemagglutinin was the first 
glycosyaminoglycan-binding protein isolated from 
lower organisms in 1950 [9]. The overview of lectins with 
carbohydrate specificity, source, and molecular weight is 
given in Table 1. 
Lectins can also be classified, based on their 
carbohydrate binding specificity, into five main 
groups with a specificity to: L-fucose, galactose/N-
acetylgalactose, sialic acids, mannose and/or glucose, 
and N-acetylglucosamine [22].
2.1 Lectin-carbohydrate interactions
Details about lectin-saccharide interactions and about 
structural basics of the carbohydrate specificity of lectins 
have been provided by several studies based on X-ray 
crystallography and other instrumental techniques 
[17,21,24,26]. Lectin-glycoconjugate biorecognition is 
specific, like in the case of antibody-antigen or enzyme-
substrate binding [10,27]. These interactions are mediated 
by hydrogen bonds, van der Waals interactions, and 
hydrophobic binding [28]. For instance, polar parts of 
galactose are recognized by a lectin through hydrogen-
bond interactions, while less polar side of galactose 
interacts with a lectin via hydrophobic interactions 
(i.e. tryptophan residues in lectin) [10]. Many lectins 
contain two or more carbohydrate-binding sites. The 
binding-sites for monosaccharides are stabilized via 
numerous hydrogen bonds, most often by Asp, Asn, and Gly 
residues [28]. Moreover, based on thermodynamic studies 
it was concluded that the dominant forces stabilizing the 
complex would appear to be intermolecular hydrogen 
bonds and van der Waals interactions [29]. Electrostatic 
interactions are limited to specific monosaccharides 
such as various forms of sialic acid [28]. In general, 
lectins exhibit low affinity (KD = 10-3–10-4  mol L-1) while 
binding with carbohydrates [30]. On the other hand, 
antigen-antibody interactions typically exhibit KD in the 
subnanomolar range [30]. 
Lectins as biorecognition elements and valuable 
glycan affinity reagents have been broadly utilized in 
numerous applications, such cancer diagnostics [18,25,31], 
drug delivery [32], immunohistological studies [28], 
analysis of pathogenic bacteria [33], HIV research [34], etc. 
Plenty of analytical techniques have been employed to study 
lectin-carbohydrate binding profiles and subtle changes 
in the glycosylation pattern. The most high-throughput 
methods in glycomics are advanced mass spectrometry 
(MS) ones combined with liquid chromatography and 
electrophoresis [14]; and lectin/carbohydrate microarrays. 
Additionally, numerous laboratory techniques have 
been adapted to integrate lectins (lectin affinity 
chromatography, enzyme-linked lectin assay (ELLA), 
lectin blotting, agglutination methods, histo- and 
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cyto-chemical methods, electrochemical impedance 
spectroscopy (EIS), quartz crystal microbalance (QCM), 
flow cytometry, surface plasmon resonance (SPR), etc.) 
for effective glycoprofiling of a diverse range of samples 
[17,35-37]. A distinct advantage of using lectin-based 
approaches compared to the instrumental techniques is 
a direct glycoprofiling of intact proteins, and even cells 
without a need to release glycans for subsequent analysis. 
Moreover, in some cases lectins can provide information 
about spatial distribution of glycans e.g. Sambucus nigra 
agglutinin (SNA) recognizes sialic acid linked to galactose 
via an α-2,6 linkage, while Maackia amurensis agglutinin 
recognizes sialic acid linked to galactose via an α-2,3 
linkage. Considering that glycan alternating motifs have 
been frequently occurred on malignant cells and tissues, 
lectins have been copiously utilized in cancer-related 
research areas. 
3 Cancer study
3.1 Glycosylation changes in cancer 
Glycan alteration is a universal feature of malignant 
transformation and tumour progression. Due to changes 
associated with a biological function, cancer cells 
frequently show fundamentally different glycan structure 
than those observed on and within normal non-malignant 
cells [9,39,40]. This change in a carbohydrate content was 
Table 1: List of lectins with their common abbreviations, source, preferred carbohydrate specificity and molecular weight [17,31,36,38].
Lectin from Abbr. S Carbohydrate specificity Mw 
Aleuria aurantia AAL A α-L-Fuc 72
Anguilla anguilla AAA F α-L-Fuc 50 
Aspergillus oryzae AOL MO α-1,6Fuc n/a
Concanavalin A Con A P α-D-Man, α-D-Glc; branched N-linked hexa-saccharide 104
Datura stramonium DSL/DSA P GlcNAcβ-1,4GlcNAc 86
Dolichos biflorus DBA P GalNAc α or β-1,3Gal 111
Erythrina cristagalli ECL/ECA P Galβ-1,4GlcNAc 54
Euonymus europaeus EEL P Galα-3Gal 140
Galanthus nivalis GNL P α-D-Man 50
Griffonia simplicifolia I GSL-I P Galα -1,3Gal 114
Griffonia simplicifolia II GSL-II P α or β-GlcNAc 113
Jacalin Jacalin (AIL) P Galβ-1,3GalNAc 66
Lens culinaris/Lentil lectin LCA P α-D-Man, α-D-Glc 50
Lotus tetragonolobus LTA/LTL P Fucα-1,2Galβ 107
Maackia amurensis I MAA/MAL P α-2,3Neu5Ac 130
Narcissus pseudonarcissus NPA/NPL P α-D-Man 59
Phaseolus vulgaris E-PHA P N-linked bi-antennary 126
Phaseolus vulgaris L-PHA P Branched β-1,6GlcNAc; N-linked tri/tetra-antennary 126
Peanut agglutinin PNA P Galβ-1,3GalNAc 110
Ricunus communis I RCA-I P β-D-Gal 120
Ricinus communis II RCA-II P Galβ-1,4GalNAc 60
Sambucus nigra SNA-I P Neu5Acα-2,6Gal/ GalNAc 140
Soybean agglutinin SBA P α or β-Gal; α or β-GalNAc 120
Ulex europaeus I UEA-I P Fucα-1,2Gal 63
Ulex europaues II UEA-II P GlcNAcβ-1,4GlcNAc 63
Vicia villosa VVL/VVA P α-D-GalNAc 144
Wheat Germ WGA P β-D-GlcNAc, Neu5Ac 36
S: source, Mw: molecular weight in kDa, A: animal, F: fungi, MO: microorganism, P: plant, Fuc: fucose, Gal: galactose, GalNAc: 
N-acetylgalactosamine, Glc: glucose, GlcNAc: N-acetylglucosamine, Man: mannose, Neu5Ac: N-acetylneuraminic acid (sialic acid)
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first described by Meezan et al.  in 1969 in a study focused 
on characterization of healthy and virus-transformed 
mouse fibroblasts [41]. 
Aberrant glycosylation results from changes in expression 
levels of glycosyltransferases in the Golgi apparatus of 
malignant cells. One of the most frequent glycan alteration 
is an increase in the size and branching of N-linked 
glycans (Fig. 1) [39]. Increasing β-1,6 branching arises 
from upregulation of N-acetylglucosaminyltransferase 
V (GnT-V) [9,42, 43]. In a lectin histochemical study, β-1,6 
branching has been correlated with the pathological 
stage in human breast and colon neoplasia [44]. While 
using the Phaseolus vulgaris leukoagglutinating lectin 
(L-PHA) it was observed that increasing branching 
is associated with metastasis resulted in decreased 
survival time in patients having colorectal cancer 
[45]. Furthermore, β-1,6 branching offers additional 
sites for attachment of terminal sialic acid residues. 
Another cancer-related change is the upregulation of 
cell surface expression of specific monosaccharides 
(N-acetylneuraminic acid, fucose) [31]. A general increased 
activity of sialyltransferases and fucosyltransferases 
leads to augmentation in the sialic acid and fucose 
content in malignant cells [46]. For instance, fucosylated 
glycoproteins are elevated in ovarian, prostate and 
colorectal cancer [47-49]. Global sialylation is often 
expressed as an increase in α-2,6-linked sialic acids 
attached to the outer Galβ-1,4-GlcNAc units on N-glycans 
or to the inner GalNAc-α1-O-Ser/Thr units on O-glycans 
[9]. Several alterations in overexpression of specific 
carbohydrate antigens, such as Lewis carbohydrate 
antigens (LeX, LeY), sialyl-LewisX (SLeX) and polysialic 
acid, have been also reported in carcinomas (Fig. 2) [9,50]. 
In a clinicopathological and immunohistochemical study, 
an increased expression of SLeX correlating with survival 
of colorectal carcinoma patients has been reported [51].
3.2 Cancer biomarkers
A biomarker is defined by the National Institute of Health 
as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, 
pathological processes, or pharmacological responses 
to a therapeutic intervention” [52]. Ideally, a biomarker 
should be able to confirm specific disease cases, detect 
the early stages of a disease and should be easily detected 
in the patient’s blood, urine or tissues. Biomarkers can 
be used as a tool to distinguish various stages of the 
disease, as an indicator of disease prognosis and as an 
index of the intensity of disease or other physiological 
state in the organism [52,53]. As a result of changes in 
the protein expression corresponding with the risk of 
a disease, biomarkers can be specific molecules or genes, 
gene products, enzymes or hormones [54]. Development 
of novel biomarkers is crucial in medical/clinical practice 
in order to increase specificity and selectivity of disease 
prognosis. 
The early detection of cancer plays the essential 
role in prognosis and patient survival and ultimately 
may affect the quality of patient’s life and the efficacy 
of used treatments. It is widely agreed that many of 
common biomarkers used nowadays in cancer diagnosis 
still lack either sensitivity or specificity or both (CA125, 
CA15-3, prostate specific antigen (PSA), carcinoembryonic 
antigen (CEA), etc.) [40]. These cancer biomarkers are 
glycosylated proteins that turn out to have aberrant 
changes in carbohydrate contents during carcinogenesis 
(Table 2). In order to find tumours at an early stage, before 
they spread and become incurable, advances in the fields 
of glycomics and proteomics can help [55]. In the future, 
glycan alterations may be used as a reliable biomarker 
and even indicate a progression of the disease. 
Interestingly, among many various cancer biomarkers 
that have been reported in scientific publications, only 
nine cancer biomarkers have been approved by the US 
FDA for clinical use [75]. Importantly, all of the following 
biomarkers are glycosylated: AFP (liver cancer), CA125 
and HE4 (ovarian cancer); thyroglobulin (thyroid cancer); 
PSA (prostate cancer); CEA (colorectal cancer); HER2/NEU 
and CA15-3/CA27-29 (breast cancer) [75,76].
3.2.1 Colorectal cancer
Colorectal cancer (CRC) is the third most commonly 
occurring cancer among men and women worldwide. 
Nowadays, flexible sigmoidoscopy, colonoscopy, double-
contrast barium enema, and blood testing for CEA (also 
Figure 1: The most common N-glycan alteration observed in 
tumourigenesis (sialylation, increased β-1,6 branching and core 
fucosylation). Structure was drawn using a program GlycoWorkbench. 
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called CEACAM5) level are broadly used for screening [77]. 
Unfortunately, some of these techniques are invasive, 
painful and uncomfortable for patients. The normal range 
for CEA value in an adult non-smoker is < 2.5 ng mL-1 and 
for smoker < 5.0 ng mL-1; a rising CEA level is associated 
with occurrence of the cancer or metastasis. However, it 
has been previously reported that CEA lacks sensitivity 
and specificity in the range of 2.5–5.0 ng mL-1 [76]. CEA is 
an oncofetal, a 180-kDa glycoprotein, normally present in 
the membranes of mucosal cells, on the luminal surface of 
the adult colon, and overexpressed in adenocarcinomas, 
especially in colorectal cancer [78]. Due to a low 
specificity of tumour associated CEA, high levels of CEA 
expression have been observed in epithelial tumour in 
the lung, breast, thyroid and ovaries [78]. CEA has 28 
N-linked glycosylation sites and during carcinogenesis 
Table 2: List of cancer biomarkers with their aberrant glycosylation.
Cancer Biomarker Type of biomarker Glycan modification Ref.
Ovarian α1-acid glycoprotein Glycoprotein Sialylation/SLeX [56]
α1-antichymotrypsin Glycoprotein Sialylation/SleX [56]
α1-antitrypsin (AAT) Glycoprotein ↑ α-2,6Neu5Ac; core fucosylation (α-1,6) [57]
CA125 (MUC16) Glycoprotein (mucin) Truncated Tn (O-linked),  sTn, [58]
core fucosylation [59]
Haptoglobin Glycoprotein Sialylation/SleX;  α-1,3Fuc, ↑ branching [56,57]
IgG Glycoprotein ↓ galactosylation and sialylation [56]
Breast CA15-3 (MUC1) Glycoprotein (mucin) Truncated Tn, sTn [60]
Colorectal β-haptoglobin Glycoprotein ↑ fucosylation [61]
CA19-9 Glycolipid High mannan structures [62]
Carcinoembryonic antigen (CEA) Glycoprotein ↑ LeX, LeY; high mannan structures [62,63]
↓ core fucosylation [64]
↑ branching, ↑ Neu5Ac [63]
Complement C3, kininogen-I Protein ↑ Neu5Ac, Fuc [65]
Pancreatic α1-β-glycoprotein Glycoprotein ↑ Neu5Ac [66]
Antithrombin-III Glycoprotein ↑ sialylation and fucosylation [67]
β-haptoglobin Glycoprotein ↑ fucosylation [68]
Kininogen-I Protein ↑ sialylation and fucosylation [67]
Prostate β-haptoglobin Glycoprotein ↑ fucosylation and branching [69]
Prostate specific antigen (PSA) Glycoprotein ↑ α-2,3 Neu5Ac  [70]
↑ α-1,2Fuc, β-GalNAc  [47]
Thyroid Thyroglobulin (Tg) Glycoprotein Terminal galactosylation, [71]
Asialylation [72]
Liver α1-antitrypsin (AAT) Glycoprotein Fucosylation [73]
α-fetoprotein (AFP) Glycoprotein Fucosylation  [73]
Transferrin Glycoprotein Fucosylation [73]
Lung β-haptoglobin Glycoprotein SLex, ↑ fucosylation [69,74]
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exhibit abnormal glycosylation [61,76]. It has been noticed 
that CEA in CRC patients contained high level of the 
blood group antigens, Lewis X (LeX) and Lewis Y (LeY) 
[63,79]. Additionally, an increased mannose expression 
and branched N-glycans were observed, as well [63]. 
In another study [64], 347 individuals were analysed, 
including CRC and colorectal adenoma patients, and 
healthy individuals. Results indicated that the level of 
total core fucose residues present on proteins in the CRC 
patients was significantly decreased compared to the 
healthy individuals [64]. 
Glycoprofiling of β-haptoglobin is another biomarker 
for early detection of colorectal carcinoma. β-Haptoglobin 
is an acute phase protein secreted into plasma which 
binds free haemoglobin to prevent haemoglobin-induced 
oxidative injury in the vascular system [80]. Human 
β-haptoglobin consists of four N-glycosylation sites and 
one O-glycosylation site [61]. Generally, the level of serum 
β-haptoglobin is enhanced in several carcinomas, but its 
abnormal carbohydrate structure is different in various 
types of cancer [61,81]. From a colon cancer viewpoint, 
increased fucosylation of β-haptoglobin in patients with 
CRC compared to the healthy individuals was observed 
[61].
3.2.2 Ovarian cancer
Ovarian cancer is the most lethal cancer among 
gynaecologic malignancies affecting women in the 
Western world and has the highest mortality rate of all 
gynaecological cancer types [82-84]. Due to several factors, 
including morphological heterogeneity, the anatomical 
position of the ovaries within the abdominal cavity, and 
the fact that approximately 70% of ovarian cancer cases 
are detected in the advanced stage III or stage IV, ovarian 
cancer is associated with a poor prognosis [76,85]. Only 
about 19% of ovarian cancer cases are detected while 
still confined to the ovary and about 7% are diagnosed 
with pelvic spread. Unfortunately, the majority of ovarian 
cancer cases (68%) are diagnosed when the cancer 
spreads over the abdomen and extra-abdominal part 
[86]. Most patients with distant metastasis are usually 
treated with maximal cytoreductive surgery [87] followed 
by chemotherapy [86]. Early detection raises the 5-year 
survival rate up to 90% while a detection at the late stage 
provides only 10–20% survival rate [59]. Therefore, it 
is urgently needed to distinguish benign cases from the 
malignant ones.. 
To date, CA125 (also called MUC16) is a routinely 
used serum marker for detection, disease progression, 
and for evaluation of a response to treatment of ovarian 
cancer [82,88]. Despite of broadly used measurement 
of the CA125 level, analysis of this tumour-associated 
glycoprotein lacks the sensitivity and specificity and has 
a limited screening capability [89]. The main limitation 
comes from the fact that an elevated CA125 level has been 
found in benign cases, such as endometriosis, pregnancy, 
ovulatory cycles, and liver diseases [59]. Advances in 
MS, electrophoretic methods, hydrophilic interaction 
liquid chromatography (HILIC), and high performance 
liquid chromatography (HPLC) allowed to explore 
differences in glycosylation status of CA125 between the 
serum from patients with ovarian cancer and the healthy 
controls. It was found that there is an increase in core-
fucosylated bi-antennary monosialylated glycans, as 
well as a decrease in non-fucosylated glycans in cancer 
patients compared to the control group [59]. In a follow 
up study using a microarray platform of analysis, specific 
aberrant O-glycoforms present on CA125 were observed. 
Glycoprofiling of CA125 showed a surface expression of 
sialyl-Thomsen-Friedenreich structures (sTn antigen, 
Neu5Acα-2,6-GalNAcα-O-Ser/Thr) and Thomsen-nouvelle 
antigen (Tn, GalNAcα-O-Ser/Thr) in patients with primary 
ovarian cancer (Fig. 2). This technique was able to 
distinguish benign cases from epithelial ovarian cancer 
with a specificity of 61.1% at 90% sensitivity [58].
HE4, a novel biomarker for efficient early stage 
detection of ovarian cancer in premenopausal patients 
[90], is slightly more specific compared to CA125 [91]. 
Several studies demonstrated that a combined clinical 
analysis of HE4 and CA125 could improve the sensitivity 
and the specificity of disease detection [91-93]. Recently, 
Figure 2: The major tumour-associated glycan structures observed in 
various types of cancer (Lewis antigens and O-glycans). Carbohydrate 
structures were created in GlycoWorkbench.
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a study on ovarian cancer has reported aberrant changes 
in glycosylation status of β-haptoglobin, α1-acid-glyco-
protein, α1-antichymotrypsin which contained elevated 
levels of sialyl Lewis X (SLeX) antigen. In this study 
it was also noticed that heavy chain of immunoglobulin 
(IgG) clearly showed core fucosylated agalactosylated 
biantennary glycan structures in patients with ovarian 
cancer, which was not present in the samples from 
the healthy control [56].
3.2.3 Prostate cancer
Prostate cancer (PCa) has been ranked globally as the 
second leading cause of death among men [83]. At 
present, prostate specific antigen (PSA) is a premier 
tumour biomarker available for prostate cancer 
diagnosis. Nevertheless, PSA is not considered as being 
a sufficiently specific biomarker for PCa detection in 
the diagnostic grey zone of 4–10  ng mL-1, and does not 
provide a clear difference between benign and malignant 
cases [94]. Due to inherent limitations of PSA testing, 
the United States Preventive Services Task Force (USPSTF) 
against PCa screening has pointed out to an urgent need 
for novel diagnostic tool with a higher specificity and 
sensitivity [95]. The new auspicious molecular biomarkers, 
such as precursor forms of PSA (proPSAs), prostate health 
index (phi), prostate cancer antigen (PCA3), TMPRSS2-
ERG gene, etc. are reflecting the growing efforts for 
improvement in clinical management of PCa [96,97]. 
Promising results of the new biomarkers generation show 
a possible supplementation or replacement of the PSA 
blood screening over time [98].
PSA (also known as hK3) is a secreted glycoprotein 
(serine-protease) with a single glycosylation site at Asn-45, 
containing approximately 8% of N-glycans [47]. Glycans 
attached to the PSA surface have been characterized as 
sialylated complex biantennary carbohydrates, mostly 
core fucosylated [99]. Circulating PSA includes formation 
of many molecular forms of PSA in human body: free PSA 
(fPSA), complexed PSA (cPSA) form with plasma proteins, 
especially serine protease inhibitor α1-antichymotrypsin, 
and inactive PSA (iPSA) [100].
Peracaula et al. presented N-glycan characterization 
of a normal PSA from seminal fluid and PCa cells using a 
sequencing analysis and mass spectrometry. The PSA from 
prostate cancer cells contained higher fucose amount, 
particularly α-1,2-Fuc-linked to galactose. Moreover, 
GalNAc was increased to 65% in the cancer samples, 
whereas in the control samples the PSA contained only 25% 
of GalNAc on carbohydrate structures [47]. Interestingly, 
another study based on elucidation of the structure of PSA 
purified from human seminal fluid revealed differential 
binding of free serum PSA to Maackia amurensis lectin. 
M. amurensis lectin recognizing α-2,3-linked sialic acid 
was increasingly bound to the prostate cancer samples 
compared to the benign prostate hypertrophy patients 
[70]. Kuno et al. published a novel practical system for 
glycan analysis with the platform based on antibody-
assisted lectin profiling. In this study, a single antibody 
assisted in: (i) immunoprecipitation; (ii) Western blotting; 
and (iii) glycan profiling by antibody-lectin microarray. 
Surprisingly, a drastic decrease in α-2,6 sialylation and an 
increase in terminal α-2,3Neu5Ac on PSA from the PCa cell 
lines were observed [101].
Since it is known that β-haptoglobin level is 
significantly enhanced in various types of cancer, the 
analysis of this acute phase protein is widely studied [61, 
68]. Fujimura et al. analysed the glycosylation status of 
β-haptoglobin in serum of PCa patients, benign prostate 
cases, and normal subjects. They noticed enhanced 
branching as well as antenna fucosylation at N-glycans in 
the PCa patients [69]. 
3.3 Current methods for glycoprofiling in  
       cancer research 
At present, there has been a rapid increase in number 
of techniques which can be applied to glycoprofiling of 
biomarkers in various types of cancer. Plentiful studies 
have employed advanced mass spectrometry (MS), 
liquid chromatography (LC), lectin or/and antibody-
based methods, microarrays techniques, electrochemical 
investigation, capillary electrophoresis (CE), microfluidic 
platforms, etc. In order to obtain a detailed, clear, and 
atomistic structure of glycans, MS based on matrix-
assisted laser desorption ionization (MALDI) or 
electrospray ionization (ESI) has been widely used. 
Samples are subsequently separated by mass/charge ratio 
using time of flight (TOF), Fourier transform ion-cyclotron 
resonance (FT-ICR) or quadrupole-based approaches, and 
finally analysed. Importantly, the purity of samples is 
an important requirement for the MS analysis, thus pre-
treatment methods are needed. The majority of the MS 
methods utilize enzymatic or chemical release of glycans 
from a protein backbone with a subsequent glycan 
modification (labeling, permethylation, separation, 
etc.), followed by MS analysis [85]. MS has recently 
emerged as an important tool in identification of novel 
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glycan biomarkers due to fast and efficient analysis, 
high sensitivity and small sample volume. Nevertheless, 
structural complexity, heterogeneity, and vast variation 
of potential carbohydrate structures require manual 
interpretation and time-consuming data evaluation [40]. 
Another promising strategy for investigation of the 
glycan structures are: lectin-based platforms (lectin 
affinity chromatography, lectin microarrays, enzyme-
linked lectin assays (ELLA), lectin histochemical staining, 
lectin blotting). The obvious benefit of application of 
lectin arrays is high-throughput detection of a minute 
amount of sample without a need for glycan removal from 
a glycoconjugate prior to analysis [17,18,40]. This approach 
is a convenient biorecognition tool for distinguishing 
between the normal and tumourigenic glycosylation 
patterns. Additionally, these lectin-based techniques have 
been used for biomarker detection and for visualization 
of cell-surface carbohydrates [13]. Unfortunately, lectin-
based formats are associated with relatively low sensitivity 
of analysis and require application of fluorescent 
labels [40]. Thus, other techniques, such as surface 
plasmon resonance (SPR) platforms, flow cytometry, 
and microfluidic systems, are increasingly employed for 
investigation of binding affinities, kinetic parameters, 
biospecific interactions, and real-time quantitative 
measurements in the field of glycomics [102,103]. 
Recently, nanotechnology has been increasingly 
utilized  to develop reliable, rapid and sensitive tools for 
biomarker detection. Due to the fact that nanomaterials 
exhibit unique optical, chemical, mechanical, and 
physical properties, it is not surprising that nanomaterials 
have been applied in biomarker analysis [104,105]. One 
of the most extensively studied nanomaterials are gold 
nanoparticles (GNPs). Since GNPs have special optical 
properties, can absorb and scatter light from the visible 
to near-infrared region, they are widely used as stable 
molecular imaging agents [104,106]. For instance, 
nontoxic nanoparticles were applied for in vivo tumour 
targeting and detection [105].
Furthermore, quantum dots (QDs), semiconducting, 
light-emitting nanocrystals, are widely exploited for 
multiplexed molecular diagnosis [105], for in vivo 
imaging [107], and for drug delivery [104,108]. QDs have 
several exceptional properties, such as resistance against 
photobleaching, simultaneous excitation of multiple 
fluorescence dyes, and nanometer scale size [104,107,108]. 
Among nanomaterials, nanoparticles like carbon 
nanotubes (CNTs) [109,110], graphene [111–113], and 
nanowires have been used most frequently [13,114,115]. 
CNTs modulate redox interfacial properties, allow label-
free detection and could be easily functionalize with many 
functional groups [104]. Besides, CNTs modified with 
multifunctional dendrimers can be applied as platforms 
in biomedical sensing, diagnosis, and for therapeutic 
purposes [13]. Park et al. designed a biosensor able to 
detect CEA biomarker using single-walled CNT field effect 
transistors (SWCNT-FETs) [116].
4 Biosensor technology
Within the last few decades biosensing has become 
a rapidly developing field involving knowledge from 
the fields of chemistry, biochemistry, biomedicine, 
biotechnology, and material sciences [117, 118]. Biosensors 
with high sensitivity and specificity, of nanoscale size and 
high speed, simple handling, and using a small volume 
of sample are rapidly developed in cancer research 
[119]. With advanced properties of nanomaterials and 
processing power of micro/opto-electronics, biosensors 
represent suitable analytical tools which can detect low 
concentrations of analytes [120-124].
The basic feature of a biosensor is the interaction of an 
analyte with a biorecognition element, which is in direct 
contact with a physico-chemical transducer. The detector 
transduces a physico-chemical signal into an electric 
output signal, proportional to the analyte concentration 
(Fig. 3). Biological molecules, including enzymes, 
antibodies/antigens, oligonucleotides, receptors, etc. [125] 
translate the information from the biochemical domain 
into a chemical or physical output signal [126]. Biosensors 
are mostly classified into several groups according to 
their transduction: (i) electrochemical (amperometric, 
impedimetric, potentiometric), (ii) optical, (iii)  mass-
detecting (piezoelectric, acoustic) and (iv) enthalpic [127]. 
Additionally, biosensors may be divided into two main 
groups based on the type of a biorecognition element. The 
first type are catalytic biosensors (enzymes, various types 
of cells and tissues) and the second group are affinity 
biosensors applying antibodies, receptors, lectins, and 
nucleic acids/aptamers as the biorecognition elements 
[120]. 
Electrochemical platforms in biosensing constitute a 
low cost, fast, and sensitive approach to the investigation 
of interactions between different biomolecules, 
which is  applied to development of molecular 
electronic devices and in the field of biotechnology, 
medicine, and pharmacy [13,119,128]. The common 
electrochemical techniques include cyclic voltammetry 
(CV), potentiometry, amperometry, and electrochemical 
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impedance spectroscopy (EIS). Additionally, differential 
pulse voltammetry (DPV) and square-wave voltammetry 
have also been applied quite frequently [13]. In recent 
decades, nanomaterials have been increasingly applied in 
many fields (molecular electronics, (bio)sensors, optical 
communications, quantum dot-based devices, biomedical 
applications, photoelectrochemical cells, etc.) [129]. 
Nanomaterials exhibit unique properties, such as reactive 
surfaces, coercive force in magnetic materials, nanoscale 
size, and high strength [130]. Many research groups have 
utilized various nanomaterial-based strategies to improve 
the detection sensitivity (e.g. graphene, nanoparticles, 
CNTs and others) [131].
4.2 Electrochemical impedance spectroscopy 
       (EIS)
EIS is a powerful technique working in a label-free mode 
for probing interfacial interactions on surface-modified 
electrodes [125]. This method was pioneered by Sluyters-
Rehbach et al. in 1969 [132]. Basically, a small sinusoidal 
potential (2–10 mV) is applied to an electrochemical cell, 
and the response of the resulting current is measured 
[13]. Consequently, impedance is calculated as the ratio 
between the system voltage U(jω) and the current signal 
I(jω), where , and ω and f are the excitation 
frequencies expressed in units rad  s–1 and Hertz (Hz), 
respectively [125]. A common way to represent a complex 
impedance is to use a sum of the real (resistive) component 
of the impedance ZRe(ω) and the imaginary (capacitive) 
part ZIm(ω). In analogy to Ohm’s law, the electrochemical 
impedance is given by:
The impedance data are typically represented in a Nyquist 
plot showing dependence of the real impedance on the 
imaginary impedance (Fig. 4). A Nyquist diagram provides 
a visual insight into the dynamics of an electrochemical 
system with a semicircle and a linear part. The semicircle 
part, at higher frequencies, matches up with an electron 
transfer-limited process whilst the linear part, at lower 
frequencies, expresses the diffusion-limited process 
[13]. If a very fast electron-transfer process is present, 
the Nyquist impedance plot could include only a  linear 
region. On the other hand, in case of a very slow electron-
transfer process, a large semicircle part without a straight 
line region is obtained [125]. A  typical equivalent circuit 
(according to the Randles and Ershler model [133]) can 
provide the resistance of the electrolyte solution, Rs, the 
double layer capacitance CPE, the Warburg coefficient Zw, 
and the electron transfer resistance, Ret (Fig. 5). 
Using a redox couple, typically a mixture of 
ferricyanide and ferrocyanide, the change in the charge 
transfer resistance Ret is obtained. Generally, the charge 
transfer resistance is inversely proportional to the rate 
of electron transfer. The double layer capacitance (CPE) 
and the charge transfer resistance (Ret) describedielectric 
and isolation features of electrode-electrolyte interface. 
However, the electrolyte resistance (Rs) and the Warburg 
impedance (Zw) characterize the properties of an 
electrolytic solution and diffusion limitation for redox 
probe to reach the electrode surface and do not affect 
electron transfer at the electrode surface. The detection 
in the broad frequencies range (10–4–106  Hz) makes 
the EIS strategy useful for diffusion analysis and for 
providing kinetics characteristics [92,118]. Generally, 
at low frequencies (f < 1 mHz) the impedance is determined 
by the DC-conductivity of the electrolyte solution and 
at higher frequencies (f  > 100  kHz), inductance of the 
electrochemical cell and connecting wires dominate the 
system [125]. 
Label-free monitoring is an indisputable advantage of 
the EIS analysis. It was observed that the labeling process 
might affect the bioaffinity between the probes and 
Figure 3: A scheme of the biosensor with an analyte, a biorecognition element, a transducer, and a detector.
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their target, resulting in a false positive/negative results 
[37,134,135]. Furthermore, the EIS detection provides 
very low limits of detection (pM–aM range) [135]. Due to 
its high sensitivity and label-free characteristics, EIS is 
gaining in popularity in lectin-carbohydrate, protein-
glycan, and antibody-antigen studies. Additionally, EIS 
has been tremendously utilized in study of corrosion, 
electrodeposition, batteries, and fuel cells [136]. EIS 
methods are employed in development and examination 
of DNA-sensors as well. DNA-sensor devices are applied 
in gene analysis, tissue matching, analysis of genetic 
disorders, and in the field of forensic [125]. The remaining 
challenges in the DNA-based biosensors are the 
modification of surfaces with different DNA-composites 
and specific detection of single-base mismatches in DNA 
sequences [125].
4.3 Immobilization techniques in biosensor  
       design
Immobilization of biomolecules plays a critical role in the 
fabrication of the biosensors and can greatly influence 
their performance. Biomolecules can be attached to 
the biosensor surface using several techniques, such 
as covalent immobilization, physical adsorption, 
bioaffinity binding, entrapment in gel, and crosslinking 
by a multifunctional reagent [137]. Physical adsorption 
of biomolecules is a reversible, simple, and fast process 
exploiting non-covalent interactions (hydrophobic forces, 
ionic binding, hydrogen bonding, and van der Waals 
interactions) [138,139]. Besides, adsorbed biomaterials 
are highly susceptible to the environmental changes (pH, 
ionic strength, temperature). Despite of the simplicity 
and the short processing time the  drawbacks of the 
immobilization method are: unfavorable orientation, 
decreased functionality/stability of biomolecules, and 
weak binding [139].
Covalent immobilization involves direct covalent 
binding between biomolecules and a  biosensor surface 
[139]. Usual working surfaces for covalent immobilization 
are chosen from a relatively small group of materials: 
metals (gold, silver, platinum), natural hydroxylic 
polymers, different carbonaceous surfaces (graphene, 
glassy carbon), glass, and silica [137]. Covalent 
immobilization may utilize chemical modification of 
the surface to create reactive functional groups, which 
react with the biorecognition molecules. Nowadays, 
amine coupling and thiol coupling are the most common 
immobilization methods in biosensing [140,141]. Light-
assisted immobilization, utilizing photolabile agents 
forming covalent bonds upon UV light activation, and 
click chemistry, involving cycloaddition of an azide and 
an alkyne, are other examples of covalent immobilization 
techniques [139,142].
4.4 Self-assembled monolayers (SAMs)
Self-assembled monolayers (SAMs) provide a well-
studied, convenient and simple system allowing for the 
density and thickness control at the transducer surface 
[139]. SAMs are organic assemblies spontaneously formed 
by strong adsorption onto a solid surface (gold, silver, 
platinum, etc.) [143]. Modification of the gold surface using 
alkanethiols with different terminal functional groups 
(-SH, -NH2 or -COOH) is currently the best characterized 
model in the SAMs strategy (Fig.  6) [139,144]. Gold is 
broadly used in electrochemistry as a standard substrate 
for SAMs due to several factors: (i) gold is a reasonably 
inert metal resisting oxidation, (ii) gold has fewer defects, 
as a substrate for SAMs fabrication, than silver or copper, 
(iii) gold is easily available as a thin film and as a colloid, 
(iv) gold substrate can be simply fabricated with different 
patterns by chemical and lithographic tools, or their 
combination [128,143,145].
A highly packed and ordered SAM can be prepared 
on surfaces using gold-thiol bonds [144]. Moreover, the 
stability of the sulphur bond with gold makes the thiol-
gold chemistry convenient for further immobilization 
reactions. It was observed that the chain length affects 
the organization of the monolayers. Hence, the addition 
of shorter alkyl derivatives may decrease the density of the 
coverage, shows a better electron transfer from the soluble 
Figure 4: A typical Nyquist plot made from EIS investigation to obtain 
key EIS characteristics. 
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redox probes and improves the electrochemical response 
of proteins and other substances [139]. Due to the high 
affinity of thiols for the noble metals, alkanethiols are 
useful and highly tunable chemicals  for biosensor surface 
modifications [143].
Additionally, SAM formation is highly sensitive to the 
pre-treatment of the metal surface. Several techniques 
of metal surface cleaning have been previously reported 
[128,146]. Such protocols may include electrochemical 
cleaning (reductive desorption of previously bound 
adsorbates, electrochemical polishing and gold oxide 
stripping), mechanical polishing of the electrode, 
chemical treatment with hot piranha solution (a mixture 
of concentrated H2SO4 and concentrated H2O2 in a 3:1 
ratio), thermal methods, etc. [128,147]. Furthermore, in 
a comparative study of nine gold cleaning methods, a 
solution of KOH + H2O2 combined with the potassium 
hydroxide potential sweep method have been found to 
deliver the cleanest gold surface [148]. 
The initial adsorption of alkanethiols on gold surface 
takes only from milliseconds to minutes, but a  slow 
reorganization phase which follows takes several hours to 
maximize the coverage density and minimize the defects 
in the SAM [143]. The most commonly used procedure for 
preparation of SAMs on gold, silver, and other materials 
is immersion of thiols for 12–18 h at room temperature 
[143]. The alkyl chains tilt at an angle of 20–30° from the 
surface normal [143,144]. Details about the mass coverage 
and organization of SAM have been provided using 
several techniques, such as atomic force microscopy 
(AFM), X-ray photoelectron spectroscopy (XPS), 
electrochemistry, scanning tunneling microscopy (STM), 
contact angle goniometry, advanced mass spectroscopy, 
etc. [139,143,144].
4.5 Amine coupling
Surface modification with SAMs allows for simple 
regeneration of the active surface and controls the 
organization of the attached probes. However, in order to 
successfully bind biomolecules, another step is required; 
i.e. activation of the terminal functional groups. One of 
the most widely used approaches to the biomolecule 
attachment is covalent binding via activation agents, 
such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC) or N,N’-dicyclohexylcarbodiimide 
(DCC) and N-hydroxysulfosuccinimide (NHS) [127,139]. 
With amine coupling, carboxyl groups on the surface 
of the functionalized material are first activated to give 
a reactive succinimide esters, then the ester spontaneously 
reacts with a primary amine of the biomolecules (Fig. 7). 
EDC/NHS chemistry is a pH dependent strategy and in 
case of protein immobilization the protein solution should 
have a pH below the pI of the protein in order to maximize 
electrostatic forces between protein and the negatively 
charged carboxyl groups [142].
Figure 5: A schematic equivalent circuit with electrochemical processes occurring on the working electrode surface (on left); Immunosensor 
based on EIS with an increase in Ret after successful immobilization of antibody (on right). 
Figure 6: A schematic diagram of SAMs on metal surface. 
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4.6 Antibody assisted lectin glycoprofiling
To date, practically three different lectin-based formats 
have been employed for studying glycosylation patterns 
in bioanalysis (Fig. 8). The direct lectin-based detection 
utilizing an immobilization of lectin onto a solid surface 
followed by an incubation with glycoprotein (Fig. 8A), 
an inverse format with adsorption of glycoproteins first 
with a subsequent incubation with lectin (Fig. 8B) and a 
sandwich configuration based on the capture of antibody 
(Ab) recognizing a glycoprotein on the surface, followed 
by an addition of a glycoprotein of interest and finally the 
incubation with lectin for the complete biorecognition to 
take place (Fig. 8C) [37].
Antibody-lectin based arrays combine the advantages 
and unique features of lectins as biorecognition elements 
with immunoreactions exhibiting high sensitivity 
towards analytes. Thus, the glycoprofiling of a particular 
biomarker can be highly specific even in quite complex 
samples. Such valuable strategy is known as the antibody-
lectin sandwich array (ALSA), pioneered by Chen et al. 
in 2007 [149]. This strategy allows for the measurement 
of the glycosylation patterns on specific glycoproteins, 
which is required for the early-stage cancer diagnostics. 
Hence, ALSA is a well suited, sensitive and comprehensive 
approach for detection of glycan alteration on a biomarker 
surface [150]. 
In the antibody related platforms the affinity constant 
and cross-reactivity of antibodies should be considered 
[151]. There are two types of antibodies, polyclonal 
and monoclonal. Monoclonal antibodies are highly 
specific to one epitope on an antigen and require quite 
a sophisticated production technology. Moreover, the 
production of monoclonal antibodies is more expensive 
and prolonged in comparison to polyclonal ones. On the 
other hand, polyclonal antibodies recognize multiple 
epitopes on any antigen [151]. Polyclonal antibodies for 
subsequent glycoprofiling of antigen have to be selected 
in a way that glycan can be still available for lectin binding 
after antibody is bound to the antigen (Fig. 9). 
The ALSA platform has naturally a few limitations, 
such as the lack of information about the precise character 
of the glycan structures and diversity of glycans at various 
attachment sites [150]. The ALSA can be directly built 
up on the already developed immunoassay formats with 
numerous advantageous characteristics [131], especially 
when combined with the electrochemical detection 
methods [151]. Thus, the ALSA approach with the support 
of advanced mass spectrometry could provide a reliable, 
highly effective, and detailed analysis of glycoproteins. 
Figure 7: A scheme of covalent attachment of the biomolecules via 
EDC/NHS surface chemistry.
Figure 8: Configuration of lectin-based analysis with applied direct 
(A), reverse (B) or sandwich immobilization protocol (C). 
Figure 9: An effective glycoprofiling of an antigen (biomarker) 
based on multiple epitopes targeting. Polyclonal antibodies will be 
selected in way to do not interfere with glycoprofiling of a particular 
glycan moiety by a lectin i.e. Ab3 will be selected for attachment of 
a biomarker for subsequent glycoprofiling of glycan close to epitope 
Ep1 by lectin. 
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4.7 Recent impedimetric-based strategies in  
       glycan analysis
Biosensors based on the electrochemical transduction 
mechanism have recently emerged as an efficient tool 
in glycan analysis. Here we provide the current trends 
in the electrochemical label-free detection of glycans 
and discuss discuss various approaches in biosensor 
construction (Table 3). 
For the first time, a label-free EIS in conjunction with 
lectins, was developed by La Belle and co-workers for 
detection of a glycan-lectin interaction [152]. A galactose-
binding lectin (PNA) and sialic acid-binding lectin (SNA) 
were covalently attached to the layered Cu/Ni/Au printed 
circuit board electrodes with a subsequent incubation of 
the lectin-modified electrode with artificial and natural 
glycoproteins. The artificial and natural glycoconjugates 
consisted of: (i) gold nanoparticles encapsulated with TF-
antigens; (ii) the glycoprotein asialofetuin (Asf) containing 
both LacNAc (Galβ-1,4GlcNAc) and TF-antigen; and (iii) 
fetuin (Fet) glycoconjugate, the sialylated glycoform of 
Asf. The EIS measurements carried out in the presence of 
the redox couple ferrocyanide/ferricyanide demonstrated 
that TF-GNP and glycoprotein Asf were rapidly and 
reliably detected down to 1 pg mL-1 (13 fM) concentration 
on the PNA-modified electrodes, while the SNA electrodes 
yielded no response. Fet glycoprotein was detected on the 
SNA-modified electrodes with a limit of detection down to 
10 pg mL-1 (150 fM) [152]. 
A label-free EIS investigation was utilized for 
a sensitive determination and evaluation of α-fetoprotein 
(AFP), a reliable biomarker for hepatocellular carcinoma 
[153]. The EIS biosensor was designed by adsorbing 
carboxyl-functionalized single-wall carbon nanotubes 
(SWNTs) onto a screen-printed carbon electrode with 
the WGA lectin being immobilized as a biomolecular 
recognition element. In order to block the surface active 
sites on the SWNT-modified electrode, bovine serum 
albumin (BSA) was applied for 30  min. Upon binding 
of AFP to a  WGA-modified electrode, Ret response was 
increased with a linear proportion to the logarithm 
of the AFP concentration in the range from 1  ng mL-1 to 
100 ng mL-1, with a limit of detection of 0.1 ng mL-1. In this 
study, the electrochemical measurements were carried out 
with the ferrocyanide/ferricyanide redox probe [153]. 
Oliveira et al. used a electrochemical biosensor for 
examination of serum glycoproteins from patients infected 
by dengue fever and from healthy individuals [154]. With 
an emphasis on improvement of the sensitivity of glycans 
detection, they modified the gold electrodes using the 
sol-gel method with integration of GNPs and a polymer. 
Furthermore, the electrodes were treated with lectin Con 
A and blocking agent BSA. The results showed a large Ret 
increase after binding of glycoproteins from the infected 
patients, and on the other hand a smaller increase in Ret 
obtained from binding of glycoproteins from the healthy 
(control) individuals [154]. 
An ultrasensitive diagnostic platform called 
“NanoMonitor” has been developed by Nagaraj´s group 
[155]. The surface of a silicon chip with an array of gold 
electrodes was modified with a  nanoporous alumina 
membrane on the top of each electrode. Using lectins 
SNA and MAA subtle glycosylation alterations of Fet 
and human pancreatic cancer cell line (BXPC-3) were 
identified. The data resulted from the NanoMonitor 
platform were correlated very well with a conventional 
laboratory technique ELLA. Due to approximately five 
orders of magnitude lower limit of detection of the 
biosensor (20  fM) compared to ELLA, a very short assay 
time (15 min) and a small sample consumption (10  µl), 
the NanoMonitor device has a  great potential in clinical 
applications [155]. 
Recently, our group constructed an impedimetric 
biosensor for the glycoprofiling of human serum 
[156]. Three different lectins (SNA, RCA, Con A) were 
covalently immobilized on the activated mixed SAMs 
layer (11-mercaptoundecanoic acid mixed with a betaine 
terminated thiol to avoid nonspecific interactions). The 
glycobiosensor was capable of detecting extremely low 
concentrations of glycoproteins, especially in a sandwich 
configuration (down to 1  aM). The EIS measurements 
revealed the distinct glycan pattern in patients with 
rheumatoid arthritis and in healthy controls. Furthermore, 
a non-specific interaction of proteins for the Con  A 
modified electrode was only 6.1% [156]. Reproducibility 
of assays by our EIS biosensors, expressed as an average 
relative standard deviation (RSD) of analysis in a diluted 
serum sample, is around 28%, which is a value similar to 
the other devices based on the screen printed electrodes 
having an average RSD of 19% [157] or 27% [158]. It is worth 
noting that this RSD is not the RSD of the assay itself, but 
rather it expresses the reproducibility of the biosensor 
preparation involving numerous steps. In a recent study 
it was shown that reproducibility of an assay by the EIS 
biosensor can be quite high with an average RSD of 4.1% 
or 7.8% for two different analytes for numerous electrodes 
present on the same chip (i.e. having an array of electrodes 
on the chip) and that the chip to chip reproducibility of an 
analysis for the same two analytes was 7.0% or 11.2% [159]. 
When a proper modification of the lectin EIS biosensor will 
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be carried out using efficient blocking agents (i.e. either 
based on proteins or other molecules having betaine or 
glycol moieties), the device should work properly with 
complex samples such as human serum. Even though 
the lectin EIS-based biosensors seem to be promising 
in analysis of a wide range of analytes and samples, so 
far it is very difficult to say whether the EIS-based lectin 
biosensors could be applied in a routine clinical assays in 
a future.
A novel label-free electrochemical impedance 
spectroscopy biosensor exploiting the interactions 
between glycans and lectin in order to analyse the 
carbohydrate expression on cancer cells was developed 
[134]. Firstly, the pre-treated electrodes were incubated 
with activated Con A with a subsequent immobilization 
of human hepatocellular carcinoma cells (Bel-7404) and 
normal liver cells (L02). This biosensor allowed to detect 
cancer cells with a detection limit of 234 cells mL-1 and was 
able to distinguish between the cancer cells and the normal 
liver cells [134]. 
A sub-pM detection limit has been reached by 
a sandwich-type electrochemical biosensor based on 
a dual-amplification of 4-mercaptophenylboronic acid-
capped gold nanoparticles (MBA-GNPs) and dopamine-
gold nanoparticles (DA-GNPs) [160]. At first, the cysteamine 
SAMs were formed on a gold disk electrode, followed by 
covering with a biotin-avidin containing film (Fig. 10). 
The capture of PSA was carried out by immobilization of 
thiolated single strand DNA1 (ssDNA1) and a subsequent 
application of a given concentration of PSA. ssDNA or RNA 
Figure 10: A scheme of the sandwich-type biotin-avidin detection based on dual amplification of MBA-GNPs and DA-GNPs. Reprinted from 
Biosensors and Bioelectronics, Copyright (2013), with permission from Elsevier [160].
Table 3: Summary of selected parameters of impedimetric biosensors.
Target Linear range Limit of detection Ref.
Asf/ Fet 13 fM – 15 pM 13 fM [152]
AFP 1–100 ng mL-1 0.1 ng mL-1 [153]
SG from patients infected by DF 10–80 dilution fold 80 dilution fold [154]
Fet/ pancreatic cancer cells (BXPC-3) n/a 20 fM [155]
SG from patients with RA aM – nM 1 aM [156]
Human liver cancer cells Bel-7404 103 –106 cells mL-1 234 cells mL-1 [134]
PSA 152 fM – 3.65 pM 50 fM [160]
Cell line K562 n/a 106 cells mL−1 [161]
Asf: asialofetuin, Fet: fetuin, AFP: α-fetoprotein, SG: serum glycoproteins, DF: dengue fever, RA: rheumatoid arthritis PSA: prostate specific 
antigen.
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aptamers could serve as biorecognition elements able to 
strongly bind to various proteins, even whole cells [160]. 
Due to a simple and controllable chemical modification 
and long-term stability, aptamers have distinct advantages 
over antibodies. 
In the last report presented here,  a microfluidic 
platform for analysis of the multi-glycan expressions on a 
cell line K562 was used [161]. In this study, indium tin oxide 
electrodes were modified with a poly(diallyldimethyl-
ammonium chloride) (PDDA) aqueous solution and 
a GNPs solution. In this step, the negatively charged GNPs 
were easily adsorbed on the PDDA-modified electrode 
surface with a positive charge. In the following step, the 
electrodes were incubated with Con A, PNA or WGA and 
BSA for 30  min. Diverse expression of carbohydrates on 
the cell surface was confirmed by the EIS measurement 
as a decreased binding ability in the order WGA < Con A 
< PNA.  [161]. 
5 Conclusions
As discussed in this article, cancer development and 
progression is associated with altered glycosylation. 
Changes in glycosylation machinery observed in various 
cancers were briefly described. One of the most common 
pathological alterations in glycosylation is an increase in 
the size and β-1,6 branching of N-linked carbohydrates 
with an increased activity of sialyltransferases and 
fucosyltransferases. 
Since the construction of lectin biosensors is a subject 
of a particular interest, EIS as a reliable, highly robust and 
sensitive detection method represent highly applicable 
tool in glycan patterning for early cancer diagnosis. 
Moreover, the EIS platform offers a label-free mode of 
operation while providing low-cost analysis and small 
sample consumption. 
Additionally, a combination of ultrasensitive 
electrochemical detection with advanced mass 
spectrometric techniques can identify novel prospective 
cancer biomarkers. Such a combined effort can provide 
an elegant way for glycoanalysis of cancer biomarkers 
with tremendous potential for highly effective cancer 
monitoring. 
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